J. Yang
5 Papers
J. Yang is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Research on the Hydrate Formation in the process of Gas Phase CO2 Pipeline Transportation
TL;DR: In this article, the CO2 hydrate formation conditions were simulated using HYSYS, and the simulation results were compared with the experimental results to verify the feasibility of the simulation method.
20
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
Mansoor Raza Mirza,X Wu,J. Zhu,Rutie Yin,J. Yang,Jie Liu,J. Wang,L Wu,Z. Liu,Y Gao,D. Wang,Gustavo Lou,H. Yang,Q. Zhou,Bowei Kong,Y. Huang,L. Chen,X. Zhen,Jianping Dong,J. Hou +19 more
TL;DR: Niraparib has previously shown efficacy in a phase 3 NORA trial, which demonstrated significantly improved PFS in patients with platinum-sensitive recurrent ovarian cancer (PSROC) as discussed by the authors .
10
A preliminary probabilistic safety assessment for ITER
Di Wang,X. D. Gong,F. Wang,J. Yang,W. J. Wang +4 more
- 01 Jan 2022
TL;DR: In this paper , the radiological risk of the International Thermonuclear Experimental Reactor (ITER), the world's largest fusion facility, has been estimated and the results show that ITER has a high frequency of accidents in the range of small dose.
1
OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
Y. Wu,Q. Zhou,M. Chen,O. Jian,Dandan Hu,Qin Lin,G.Y. Wu,Jiuwei Cui,J W C Chang,Y. Cheng,C. Huang,A. Liu,Nan Yang,Yixuan Gong,C. Zhu,Z.S. Ma,J. Fang,G. Chen,J. Zhao,Anhui Shi,Y. Lin,G Li,Yi Liu,D. Wang,R. Wu,X Xu,J. Shi,Z. Liu,J. Wang,J. Yang +29 more
TL;DR: Sugemalimab as discussed by the authors is a full-length, fully human IgG4 monoclonal antibody targeting PD-L1. GEMSTONE-301 is an ongoing phase 3 trial to evaluate sugemalimrab as a consolidation treatment in patients(pts) with stage III NSCLC without disease progression following chemoradiotherapy (CRT).